Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
|
|
- Theodora Quinn
- 6 years ago
- Views:
Transcription
1 Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
2 Faculty John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical University of South Carolina Charleston, SC 2
3 Disclosures John M. Wharton, MD serves on the research support team for Pfizer, Bristol-Myers Squibb, Biosense Webster, and Toray Industries. Dr. Wharton also serves as a speaker for Medtronic. 3
4 Learning Objectives 1. Identify those patients at risk for cardioembolic stroke who are appropriate candidates for anticoagulation 2. Recognize common misperceptions about anticoagulation risk to improve communication and patient adherence 3. Discuss the management of bleeding in patients on anticoagulants 4. Describe the role of continued anticoagulation in the setting of emerging non-pharmacologic therapy 4
5 PRE-TEST QUESTIONS 5
6 Consider a 67 y/o woman with AF and no other medical problems. What is the CHA2DS2-VASc score and should oral anticoagulant be prescribed? CHA2DS2-VASc Score Pre-test Question 1 Anticoagulate? 1. 0 No 2. 1 No 3. 1 Yes 4. 2 No 5. 2 Yes 6. 3 Yes 6
7 Pre-test Question 2 Consider a 75 y/o man with persistent AF, history of HF, CAD, HTN, CKD, and PAD. Treated with warfarin but INRs difficult to keep in the therapeutic range. HAS-BLED score 4, which = 8%-10% annualized risk for major bleeding. Would you treat this patient with: 1. No antiplatelet agent or oral anticoagulant because of his risk of bleeding 2. An antiplatelet agent because of his risk of bleeding 3. A DOAC despite his risk of bleeding 4. A reduced dosage of DOAC because of his risk of bleeding 7
8 Pre-test Question 3 Consider a 62 y/o woman with paroxysmal AF, HTN, T2DM, and GERD, treated with rivaroxaban. Presents to ED with repeated hematemesis of bright red blood, hypotension, and Hgb 6.1 gm/dl. Last dose of rivaroxaban 1 hour earlier. Which of the following would be appropriate to treat her bleeding? 1. Give activated charcoal by NG tube 2. Give intravenous fluid and blood and emergent GI consult 3. Give fresh frozen plasma 4. Give idarucizumab 5. 1 and , 2, and 3 8
9 Pre-test Question 4 A 78 y/o man with persistent AF undergoes successful ablation of AF and atrial flutter. Anticoagulated with dabigatran and takes aspirin for CAD without bleeding complications. History of prior MI, mild HF, HTN, and PAD. One month of loop monitoring 4 months after his ablation was normal. What would you do with his oral anticoagulation: 1. Stop his dabigatran and his aspirin 2. Stop his dagibatran but continue his aspirin 3. Continue his dabigatran and his aspirin 4. Continue his dagibatran but stop his aspirin 9
10 Pre-test Question 5 Please rate your confidence in your ability to assess stroke risk and manage anticoagulation in patients with atrial fibrillation: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 10
11 Agenda Estimating Stroke Risk Safety and Efficacy of Oral Anticoagulants Other Options for Stroke Prevention The Role of Primary Care 11
12 Patient Case: Ann Presentation 64-year-old woman with recent diagnosis of AF Retired editor Married, 3 adult children Presented to ED last week with dizziness and palpitations Treated with IV diltiazem and discharged Duration of AF ~6 hours Medical History Hypertension, 15 years T2DM, 6 years No history of stroke or major bleeding 12
13 Ann (cont d) Workup BP 120/72 mmhg BMI 25.5 kg/m 2 HR 72 bpm Normal sinus rhythm Lungs clear on auscultation A1C 7.2% Current medications Lisinopril/hydrochlorothiazide 20/25 mg qd Calcium and vitamin D supplement Managing T2DM with diet and daily exercise 13
14 AF, Strokes, and Cognitive Decline Worse Outcomes with Embolic Strokes Major cause of strokes in elderly >70,000 strokes per year in US 15% of strokes in US due to AF 5% of AF patients have symptomatic and 15-25% have asymptomatic strokes Stroke risk persists in asymptomatic patient with AF Dementia increased 2-3X with AF Lin HJ et al. Stroke. 1996;27(10): Fuster V, et al. JACC 2001;38: ; Benjamin EJ, et al. Circulation 1998;98:946-52; Duli DA, et al. Neuroepidemiol 2003;22:118-23; Page RL, et al. Circulation 2003;107: ; Cha M-J, et al. Am J Cardiol 2014;113:
15 Stroke Risk and AF Duration from Implantable Device Diagnostics Study AF Duration RR (95% CI) p Value TRENDS 1 20 second - <5.5 hours 0.98 (0.34,2.82) hours 2.20 (0.96,5.05) 0.06 ASSERT 2 6 minutes 1.77 (1.01,3.10) minutes 1.87 (1.06,3.28) hours 2.01 ( ) hours 1.86 (1.05,3.29) hours 1.98 (1.13,3.49) hours 1.93 (1.09,3.42) Glotzer T, et al. Circ Arrhythmia Electrophysiol 2009;2: Gold MR, et al. Heart Rhythm 2012;9:S24 (Abstract). Ø 1 TRENDS: N = Ø 2 ASSERT: N =
16 Risk of Stroke Assessed by CHADS 2 Score CHADS2 Points C = CHF 1 H = HTN 1 A = Age 75 1 D = DM 1 S = Prior CVA 2 Stroke Rate (% per year) n=120 1 n=463 2 n=523 3 n=337 4 n=220 5 n=65 6 n=5 CHADS 2 Score Fuster V et al. J Am Coll Cardiol. 2011;57(11):e101-e
17 Comparison of CHADS2 and CHA2DS2- VASc Scoring Systems Scoring System Annualized Stroke Risk CHADS2 CHA2DS2 -VASc Risk Factor Points Points CHF 1 1 Hypertensi on 1 1 Age > Diabetes 1 1 Prior Stroke Vascular Disease Age Female Total Score CHADS2 CHA2DS 2-VASc Lip GY, Halperin JL. Am J Med 2010;123(6):84-488; Olesen JB, et al. Br Med J 2011;342:d
18 2014 ACC/AHA/HRS AF Guidelines: Recommendations for Anticoagulation CHA2DS2- VASc* Recommended Anticoagulation 0 No therapy 1 No therapy; warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, or ASA may be considered 2 Valvular Disease Warfarin, dabigatran, rivaroxaban, apixaban, edoxaban Warfarin with INR January CT, et al. Circulation 2014;129: Doi; /CIR ACC/AHA Clinical Performance and Quality Measures state CHA2DS2-VASc score must be documented and shared decision making documented Heidenriech PA, et al. J Am Coll Cardiol 2016 (in press). doi.org/ /j.jacc
19 Warfarin Remains Underutilized Retrospective cohort study of 171,393 patients to assess the utilization of warfarin within 30 days of an AF/flutter diagnosis among different risk strata* Total (n=171,393) Newly Diagnosed AF/Flutter (n=51,907) Pre-Existing AF/Flutter (n=119,486) Treated with Warfarin (%) Low Risk 59.9% Untreated Moderate Risk 56.5% Untreated High Risk 57.9% Untreated CHADS 2 Score *Hatched area represents the proportion of patients with uninterrupted therapy over 180 days following initial warfarin prescription. 19 Zimetbaum PJ, et al. Am J Med. 2010;123(5):
20 Anticoagulation and DOACS Ø What does the data say? 20
21 Anticoagulation in AF Stroke Risk Reductions (N= 2900) Warfarin Better Control Better AFASAK SPAF BAATAF Reduction of all-cause mortality RRR 26% CAFA SPINAF EAFT Aggregate Reduction of stroke RRR 62% 100% 50% 0-50% -100% Hart et al. Ann Intern Med 1999;131:
22 Narrow Therapeutic-Safety Window With Warfarin Assessed by INR Measurement 20 Therapeutic Window Odds Ratio Intracranial Bleeding 5 Ischemic Stroke INR ICH is the most lethal form of stroke with 30-day mortality rates of 30-55% 1,2 Adapted from Fuster V, et al. J Am Coll Cardiol 2011;57(11):e101-e198. Modified with permission from Hylek EM, Singer DE. Ann Intern Med 1994;120: Data from Odén A, Fahlén M, Hart RG. Thromb Res 2006;117: Freeman WD, Aguilar MI. Expert Rev Neurother 2008;8(2): Aguilar MI, et al. Mayo Clin Proc 2007;82(1):
23 Antiplatelet Therapy in AF ACTIVE-W: 6706 randomized patients; trial stopped ACTIVE-A: 7554 randomized patients; median follow-up of 3.6 years 8 P =.01 Outcome/Year (%) P =.0003 Clopidogrel + ASA Warfarin P =.001 P =.53 Outcome/Year (%) Clopidogrel + ASA ASA P<.001 P< Vascular Event Stroke Major Bleeding 0 Vascular Event Stroke Major Bleeding ACTIVE = AF Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. ACTIVE Investigators. Lancet. 2006;367: ACTIVE Investigators. N Engl J Med. 2009;360(20):
24 Newer Anticoagulants Activated Factor X Inhibitors Apixaban Betrixaban Edoxaban Novel Vitamin K Antagonist Rivaroxaban *Warfarin Extrinsic Pathway Activation Intrinsic Pathway Activation Factor X Factor Xa Factor X Direct Thrombin Inhibitors Activated Factor X Inhibitors Prothrombin Thrombin Dabigatran Etexilate Direct Thrombin Inhibitors Fibrinogen Fibrin Ma TKW, et al. Pharmacology and Therapeutic 2010; doi; /j.pharmthera
25 Comparison of Efficacy and Safety of DOAC s to Warfarin: Meta-Analysis of Randomized Trials Ø Strokes and Systemic Emboli Ø Ø Major Bleeding Ø Ruff CT, et al. Lancet 2014; 383(9921): Ø 25
26 Annual Risk* of Fatal Bleeding with DOACs DOAC Warfarin RR (95% CI) p Value RE-LY: 150 mg ( ) 0.15 ROCKET-AF ( ) <0.001 ARISTOTLE ( ) < ENGAGE-AF: 60 mg ( ) <0.001 *Percent of patients/year 1) Connolly SJ, et al. N Engl J Med 2009; 361: ) Patel MR, et al. N Engl J Med 2011;365(10): ) Granger CB, et al. N Engl J Med 2011;365(11): ) Giugliano RP, et al. N Engl J Med 2013;369:
27 Pairwise, Propensity Matched Comparison of DOAC s to Warfarin in Large US Insurance Database DOAC vs Warfarin N=76,354 EFFICACY Stroke + Systemic Emboli Apixaban N=7695 Dabigatran N=14,307 Rivaroxaban N=16, ( )* 0.98 ( ) 0.93 ( ) Ischemic Stroke 0.83 ( ) 1.06 ( ) 1.01 ( ) Hemorrhagic Stroke SAFETY Major Bleeding 0.45 ( )*** Intracranial Bleeding 0.35 ( )* 0.56 ( ) 0.61 ( ) 0.24 ( )*** GI Bleeding 0.51 ( )*** 0.79 ( )** 1.04 ( ) 0.36 ( )*** 0.51 ( )*** 1.03 ( ) 1.21 ( )* Ø *p<0.05. **P<0.01. ***P< Ø Yao X, et al. J Am Heart Assoc 2016:5:e Ø 27
28 HAS-BLED Bleeding Risk Score Letter Clinical Characteristic Score H Hypertension 1 A Abnormal Renal and Liver Function (1 point each) 1 or 2 S Stroke 1 B Bleeding 1 L Labile INR 1 E Elderly (age >65 yrs) 1 D Point Score System Drugs and Alcohol (1 point each) 1 or 2 Bleeding Risk Score Bleeding Risk* Camm AJ, et al. Eur Heart J 2010;31(19): Pisters R. Chest. 2010;138: Lip GY, et al. Am J Med. 2010;123(6):
29 Utility of CHA 2 DS 2 -VASc in Predicting Major Bleeding Risk with Oral Anticoagulation Risk of Thromboembolism and Any Severe Bleeding in Stockholm Annualized Percent Risk CHA2DS2-VASc Score However, HAS-BLED has much higher discriminatory performance for predicting major bleeding compared to CHADS2 or CHA2DS2-VASc scores Forslund T, et al. Eur J Clin Pharmacol 2014;70: ; Apostolakis S, et al. Thromb Haemost 2013;110: ; Roldan V, et al. J Am Coll Cardiol 2013;62:
30 To Bridge or Not to Bridge 30
31 Transient Interruption of Oral Anticoagulants Prior to Procedures Risk of stroke is increased with transient discontinuation of OAC in high risk AF patients All DOAC s have a black box warning cautioning about this risk Post hoc analyses do not demonstrate a greater risk than with warfarin discontinuation Possible role of bridging therapy not well studied Major goal Limit duration of interruption as much as is safely possible 31
32 Periprocedural Bridging Anticoagulation* During Warfarin and Dabigatran Interruption in RE-LY Ø Percent of Patients with Event Ø Stroke or Major Bleeding Ø Systemic Embolus Ø P=NS P=NS Ø P<0.001 P<0.001 *Using low molecular weight heparin or unfractionated heparin Douketis JD, et al. Thromb Haemost 2015;113:
33 Potential Reversal Agents of DOACs for Severe or Life-threatening Bleeding Intervention Dabigatran Rivaroxaban Apixaban Edoxaban Oral activated charcoal Yes Yes Yes Yes Hemodialysis Yes No No? Hemoperfusion with activated charcoal Yes Possible Possible? Fresh frozen plasma No No No No PCC-4 factor* Possible Possible Possible Possible Idarucizumab Yes No No No Andexanet-alfa** No Yes Yes Yes *4 factor prothrombin complex concentrate is not FDA approved for DOAC reversal **Investigational drugs Ansell JE. J Thromb Thrombolysis 2015 (Oct 15). 33
34 Should Patient After AF Ablation Be CHADS2 Score Chronically Anticoagulated? Retrospective Analysis of the Effect of AF Ablation on Stroke Risk No AF (n = 16848) AF Medical (n = 16848) AF Ablation (n = 4212) p Value 0 2.6% 3.7% 1.6% < % 5.4% 1.9% < % 2.2% < % 9.0% 6.1% % 17.6% 9.1% < % 18.6% 13.2% 0.18 Bunch TJ, et al. Heart Rhythm 2013 DOI:10:1016/j.hrthm There are no prospective, randomized trials demonstrating the efficacy or safety of catheter ablation for stroke prevention in AF patients. 34
35 Final Points 35
36 Summary: Use of Oral Anticoagulants in Patients with AF OAC s are underutilized despite their benefits Efficacy and safety of OAC s depend upon accurate assessment of stroke and bleeding risks Document CHA2DS2-VASc score and shared decision process The higher the stroke risk, the greater the relative benefit of OAC, despite the risks of bleeding Major bleeding in patients on DOAC s is treated with conventional supportive therapy and correction of bleeding source; only warfarin and dabigatran have approved reversal agents AF ablation is not an alternative to anticoagulation in high risk patients and LAAC devices are limited to patients who are truly intolerant to or incapable of taking OAC s 36
37 POST-TEST QUESTIONS 37
38 Post-test Question 1 Consider a 67 y/o woman with AF and no other medical problems. What is the CHA2DS2-VASc score and should oral anticoagulant be prescribed? CHA2DS2-VASc Score Anticoagulate? 1. 0 No 2. 1 No 3. 1 Yes 4. 2 No 5. 2 Yes 6. 3 Yes 38
39 Post-test Question 2 Consider a 75 y/o man with persistent AF, history of HF, CAD, HTN, CKD, and PAD. Treated with warfarin but INRs difficult to keep in the therapeutic range. HAS-BLED score 4, which = 8%-10% annualized risk for major bleeding. Would you treat this patient with: 1. No antiplatelet agent or oral anticoagulant because of his risk of bleeding 2. An antiplatelet agent because of his risk of bleeding 3. A DOAC despite his risk of bleeding 4. A reduced dosage of DOAC because of his risk of bleeding 39
40 Post-test Question 3 Consider a 62 y/o woman with paroxysmal AF, HTN, T2DM, and GERD, treated with rivaroxaban. Presents to ED with repeated hematemesis of bright red blood, hypotension, and Hgb 6.1 gm/dl. Last dose of rivaroxaban 1 hour earlier. Which of the following would be appropriate to treat her bleeding? 1. Give activated charcoal by NG tube 2. Give intravenous fluid and blood and emergent GI consult 3. Give fresh frozen plasma 4. Give idarucizumab 5. 1 and , 2, and 3 40
41 Post-test Question 4 A 78 y/o man with persistent AF undergoes successful ablation of AF and atrial flutter. Anticoagulated with dabigatran and takes aspirin for CAD without bleeding complications. History of prior MI, mild HF, HTN, and PAD. One month of loop monitoring 4 months after his ablation was normal. What would you do with his oral anticoagulation: 1. Stop his dabigatran and his aspirin 2. Stop his dagibatran but continue his aspirin 3. Continue his dabigatran and his aspirin 4. Continue his dagibatran but stop his aspirin 41
42 Post-test Question 5 Please rate your confidence in your ability to assess stroke risk and manage anticoagulation in patients with atrial fibrillation: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 42
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical University
More informationEmerging Challenges in Primary Care : 2017
Ø 5/9/17 Emerging Challenges in Primary Care : 2017 Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices Faculty Barbara Hutchinson, MD, PhD, FACC President, Association of Black
More informationEmerging Challenges in Primary Care : Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Emerging Challenges in Primary Care : 2017 Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices Faculty Barbara Hutchinson, MD, PhD, FACC President, Association of Black Cardiologists
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationAtrial Fibrillation in the Emergency Department
Atrial Fibrillation in the Emergency Department Disclosures Edward Jauch, MD MS Research support National Institutes of Health funding (multiple trials) Novo Nordisk (drug in kind) STOP-IT Study Genentech
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationManaging Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationEmerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Preventing Stroke in Patients with Atrial Fibrillation: New Concepts and Controversies 1 Faculty Elizabeth A. Jackson, MD, MPH Associate Professor of
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationSpontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
More informationAtrial Fibrillation. E. Kevin Heist, MD, PhD. Updates in General Internal Medicine for Specialists January 28, 2019
Atrial Fibrillation E. Kevin Heist, MD, PhD Updates in General Internal Medicine for Specialists January 28, 2019 Disclosures Abbott Consultant, Research Grant Biotronik Consultant Boston Scientific Consultant
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationTREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS. Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai
TREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai Acknowledgement Many of the slides for this presentation were obtained
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationModeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD
Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD Mount Sinai School of Medicine New York, NY Session II. Weighing the Risks and Benefits
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationUse of Anticoagulants in Geriatrics: Current Evidence and Special Considerations
Use of Anticoagulants in Geriatrics: Current Evidence and Special Considerations Aryn You, PharmD Assistant Professor, Pharmacy Practice The Daniel K. Inouye College of Pharmacy Aida Wen, MD Associate
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationDisclosures. Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation
12:45 1:45 pm Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation SPEAKER Christian Ruff, MD, MPH Presenter Disclosure Information
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationAnticoagulation for Arrhythmia
Anticoagulation for Arrhythmia Paul Khairy, MD, PhD Scientific Director, Adult Congenital Center Professor of Medicine and Research Chair, University of Montreal Atrial Arrhythmia Lightening the Burden
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Atrial Fibrillation Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic UC SF Division of
More informationPharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Disclosures None Risk of
More informationSTROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke
(%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationFact or Fiction? All Patients Will Use NOACS Instead of Warfarin in 10 Years:
All Patients Will Use NOACS Instead of Warfarin in 10 Years: Fact or Fiction? Cash Casey, MD Advocate Medical Group/ Midwest Heart Specialists December 3 rd, 2016 Disclosures Advisory board/speakers bureau:
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More information